Fluticasone Propionate via Diskus™ Inhaler at Half the Microgram Dose of Budesonide via Turbuhaler™ Inhaler.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      Objective: To evaluate the efficacy and tolerability of two inhaled corticosteroid treatment regimens, fluticasone propionate (FP) delivered from a Diskus™ inhaler and budesonide delivered from a Turbuhaler™ inhaler, in adult patients with asthma. Design and Setting: This was an open, randomised, multicentre, parallel group study conducted in nine countries. Patients: 277 patients with asthma, aged 18 to 87 years, with mean baseline forced expiratory volume in 1 second (FEV) 75% predicted and treated with 400 to 1200 µg/day of inhaled corticosteroid, were randomised to treatment. Interventions: 137 patients received FP 250µg twice daily from a Diskus™ inhaler and 140 received budesonide 600µg twice daily from a Turbuhaler™ inhaler for 4 weeks. Results: No significant differences were seen between the two treatments for mean morning peak expiratory flow recorded on a daily record card [95% confidence limit (CL) for difference -5.1, 11.3 L/min, p = 0.46] or for any other efficacy parameter. A significant difference in adjusted geometric mean morning serum cortisol level after 4 weeks' treatment was seen in favour of FP (ratio of FP adjusted mean to budesonide adjusted mean 1.29, 95% CL 1.14, 1.47 nmol/L, p < 0.001). Device handling assessments favoured the Diskus™ inhaler over the Turbuhaler™ inhaler; 81% of patients used the Diskus™ inhaler correctly first time compared with 61% for the Turbuhaler™ inhaler. Conclusions: Administration of FP at less than half the microgram dosage of budesonide was as effective and caused less hypothalamic-pituitary-adrenal axis suppression measured by serum cortisol levels. The Diskus™ inhaler was also generally rated more highly by patients than the Turbuhaler™ inhaler. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Clinical Drug Investigation is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)